Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
出版年份 2021 全文链接
标题
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-28
DOI
10.1038/s41375-021-01421-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
- (2021) Spyridoula Vasileiou et al. JOURNAL OF CLINICAL ONCOLOGY
- The Next Decade of Immune Checkpoint Therapy
- (2021) Padmanee Sharma et al. Cancer Discovery
- Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
- (2021) Martin Thelen et al. npj Precision Oncology
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
- (2020) Paul J. Bröckelmann et al. JAMA Oncology
- Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58
- (2020) Johanna Veldman et al. BLOOD
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
- (2020) Jeffrey C Thompson et al. Journal for ImmunoTherapy of Cancer
- The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma
- (2020) Joji Nagasaki et al. Blood Advances
- Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
- (2020) Sarah Reinke et al. BLOOD
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
- (2020) Layal El Halabi et al. Clinical Lymphoma Myeloma & Leukemia
- Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
- (2019) Jing Nie et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
- (2019) Yuqin Song et al. LEUKEMIA
- The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative
- (2019) Sanjay S. Patel et al. BLOOD
- Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
- (2019) Tomohiro Aoki et al. Cancer Discovery
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
- (2018) Ludmila Danilova et al. Cancer Immunology Research
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction and transcriptional regulation of the co-inhibitory gene module in T cells
- (2018) Norio Chihara et al. NATURE
- Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
- (2018) Nataly Manjarrez-Orduño et al. Frontiers in Immunology
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
- (2017) Marcel Nijland et al. OncoImmunology
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints
- (2016) S. Vardhana et al. HAEMATOLOGICA
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints
- (2016) S. Vardhana et al. HAEMATOLOGICA
- PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma
- (2015) Vehbi Ercolak et al. ACTA HAEMATOLOGICA
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
- (2014) J. Reichel et al. BLOOD
- Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein–Barr virus-specific T cells as targets of interest in immunotherapeutic approaches
- (2014) Sabine Tischer et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens
- (2013) N. Masque-Soler et al. BLOOD
- Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients
- (2012) Riguel J. Inaoka et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
- (2011) Ulrike Gerdemann et al. MOLECULAR THERAPY
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started